Similar to the findings for NSE, it was found that the frequency of elevated NE (i.e., NE > 385 pg/mL) in groups such as voluntary blood donors, patients with T2DM before COVID-19, and patients with advanced-stage nephropathy before COVID-19 was comparable and lower than in the group of patients with advanced nephropathy who had recovered from COVID-19. This evidence concerns the gene ENO2 and Nephropathy.